NBY
NovaBay Pharmaceuticals, Inc.
Biotechnology
Market Cap$11M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NBY vs OGEN
Revenue, margins, valuation, and 5-year total return — side by side.
OGEN
Oragenics, Inc.
Biotechnology
Market Cap$3M
5Y Perf.-99.9%
NBY vs OGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NBY | OGEN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $11M | $3M |
| Revenue (TTM) | $3M | $0.00 |
| Net Income (TTM) | $3M | $-10M |
| Gross Margin | 54.6% | — |
| Operating Margin | -273.0% | — |
| Total Debt | $2M | $227M |
| Cash & Equiv. | $430K | $4.40B |
NBY vs OGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NBY
OGEN
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| NovaBay Pharmaceuti… (NBY) | 100 | 0.0 | -100.0% |
| Oragenics, Inc. (OGEN) | 100 | 0.1 | -99.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NBY vs OGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NBY leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Oragenics, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NBY
NovaBay Pharmaceuticals, Inc.
The Growth Play
NBY carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -6.4%, EPS growth 98.2%, 3Y rev CAGR -1.4%
- -100.0% 10Y total return vs OGEN's -100.0%
- -6.4% revenue growth vs OGEN's -38.6%
Best for: growth exposure and long-term compounding
OGEN
Oragenics, Inc.
The Income Pick
OGEN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 2 yrs, beta 2.29
- Lower volatility, beta 2.29, Low D/E 2.7%, current ratio 44.28x
- Beta 2.29, current ratio 44.28x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NBY | -6.4% revenue growth vs OGEN's -38.6% |
| Quality / Margins | NBY | 114.6% margin vs OGEN's -0.0% |
| Stability / Safety | OGEN | Beta 2.29 vs NBY's 2.43 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NBY | +102.8% vs OGEN's -88.0% |
| Efficiency (ROA) | NBY | 93.0% ROA vs OGEN's -0.4%, ROIC -217.0% vs -0.3% |
NBY vs OGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2023
NBY vs OGEN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNBYLAGGINGOGEN
OGENOragenics, Inc.
2leads
NBYNovaBay Pharmaceutica…
3leads
6 Total Categories
CATEGORYLEADERvs OGENMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NBY1/1
Valuation MetricsMultiples, price ratios, and targets
NBY1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OGEN5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NBY5/6
Risk & VolatilityBeta, volatility, and downside exposure
OGEN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NBY leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NBY and OGEN operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | NBYNovaBay Pharmaceu… | OGENOragenics, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $3M | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$6M |
| Net IncomeAfter-tax profit | $3M | -$10M |
| Free Cash FlowCash after capex | -$7M | -$9.2B |
| Gross MarginGross profit ÷ Revenue | +54.6% | — |
| Operating MarginEBIT ÷ Revenue | -2.7% | — |
| Net MarginNet income ÷ Revenue | +114.6% | — |
| FCF MarginFCF ÷ Revenue | -2.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -78.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +63.3% | -5.9% |
NBY leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NBY leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | NBYNovaBay Pharmaceu… | OGENOragenics, Inc. |
|---|---|---|
| Market CapShares × price | $11M | $3M |
| Enterprise ValueMkt cap + debt − cash | $13M | -$4.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.74x | -0.13x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.16x | — |
| Price / BookPrice ÷ Book value/share | — | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
NBY leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
OGEN leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
NBY delivers a 198.5% return on equity — every $100 of shareholder capital generates $198 in annual profit, vs $-0 for OGEN. On the Piotroski fundamental quality scale (0–9), OGEN scores 5/9 vs NBY's 3/9, reflecting solid financial health.
| Metric | NBYNovaBay Pharmaceu… | OGENOragenics, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +198.5% | -0.5% |
| ROA (TTM)Return on assets | +93.0% | -0.4% |
| ROICReturn on invested capital | -2.2% | -0.3% |
| ROCEReturn on capital employed | -2.2% | -0.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | $1M | -$4.2B |
| Cash & Equiv.Liquid assets | $430,000 | $4.4B |
| Total DebtShort + long-term debt | $2M | $227M |
| Interest CoverageEBIT ÷ Interest expense | -89.97x | -11.80x |
OGEN leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NBY leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NBY five years ago would be worth $13 today (with dividends reinvested), compared to $5 for OGEN. Over the past 12 months, NBY leads with a +102.8% total return vs OGEN's -88.0%. The 3-year compound annual growth rate (CAGR) favors NBY at -67.4% vs OGEN's -80.6% — a key indicator of consistent wealth creation.
| Metric | NBYNovaBay Pharmaceu… | OGENOragenics, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -93.6% | -27.0% |
| 1-Year ReturnPast 12 months | +102.8% | -88.0% |
| 3-Year ReturnCumulative with dividends | -96.5% | -99.3% |
| 5-Year ReturnCumulative with dividends | -99.9% | -99.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -67.4% | -80.6% |
NBY leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
OGEN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
OGEN is the less volatile stock with a 2.29 beta — it tends to amplify market swings less than NBY's 2.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OGEN currently trades 6.4% from its 52-week high vs NBY's 1.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NBYNovaBay Pharmaceu… | OGENOragenics, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.43x | 2.29x |
| 52-Week HighHighest price in past year | $99.75 | $9.60 |
| 52-Week LowLowest price in past year | $1.11 | $0.50 |
| % of 52W HighCurrent price vs 52-week peak | +1.9% | +6.4% |
| RSI (14)Momentum oscillator 0–100 | 42.5 | 45.6 |
| Avg Volume (50D)Average daily shares traded | 595K | 159K |
OGEN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NBYNovaBay Pharmaceu… | OGENOragenics, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NBY leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). OGEN leads in 2 (Profitability & Efficiency, Risk & Volatility).
Best OverallNovaBay Pharmaceuticals, In… (NBY)Leads 3 of 6 categories
Loading custom metrics...
NBY vs OGEN: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NBY or OGEN?
Over the past 5 years, NovaBay Pharmaceuticals, Inc.
(NBY) delivered a total return of -99. 9%, compared to -99. 9% for Oragenics, Inc. (OGEN). Over 10 years, the gap is even starker: NBY returned -100. 0% versus OGEN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NBY or OGEN?
By beta (market sensitivity over 5 years), Oragenics, Inc.
(OGEN) is the lower-risk stock at 2. 29β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately 6% more volatile than OGEN relative to the S&P 500.
03Which is growing faster — NBY or OGEN?
On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc.
grew EPS 98. 2% year-over-year, compared to -185. 0% for Oragenics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NBY or OGEN?
Oragenics, Inc.
(OGEN) is the more profitable company, earning 0. 0% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OGEN leads at 0. 0% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NBY or OGEN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NBY or OGEN better for a retirement portfolio?
For long-horizon retirement investors, NovaBay Pharmaceuticals, Inc.
(NBY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Oragenics, Inc. (OGEN) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NBY: -100. 0%, OGEN: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NBY and OGEN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.